Cargando…
Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets
BACKGROUND: Epilepsy is a chronic neurological disorder that affects approximately 50–70 million people worldwide. Epilepsy has a significant economic and social burden on patients as well as on the country. The recurrent, spontaneous seizure activity caused by abnormal neuronal firing in the brain...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662271/ https://www.ncbi.nlm.nih.gov/pubmed/38020406 http://dx.doi.org/10.1177/09727531231185991 |
_version_ | 1785138171497938944 |
---|---|
author | Belete, Tafere Mulaw |
author_facet | Belete, Tafere Mulaw |
author_sort | Belete, Tafere Mulaw |
collection | PubMed |
description | BACKGROUND: Epilepsy is a chronic neurological disorder that affects approximately 50–70 million people worldwide. Epilepsy has a significant economic and social burden on patients as well as on the country. The recurrent, spontaneous seizure activity caused by abnormal neuronal firing in the brain is a hallmark of epilepsy. The current antiepileptic drugs provide symptomatic relief by restoring the balance of excitatory and inhibitory neurotransmitters. Besides, about 30% of epileptic patients do not achieve seizure control. The prevalence of adverse drug reactions, including aggression, agitation, irritability, and associated comorbidities, is also prevalent. Therefore, researchers should focus on developing more effective, safe, and disease-modifying agents based on new molecular targets and signaling cascades. SUMMARY: This review overviews several clinical trials that help identify promising new targets like lactate dehydrogenase inhibitors, c-jun n-terminal kinases, high mobility group box-1 antibodies, astrocyte reactivity inhibitors, cholesterol 24-hydroxylase inhibitors, glycogen synthase kinase-3 beta inhibitors, and glycolytic inhibitors to develop a new antiepileptic drug. KEY MESSAGES: Approximately 30% of epileptic patients do not achieve seizure control. The current anti-seizure drugs are not disease modifying, cure or prevent epilepsy. Lactate dehydrogenase inhibitor, cholesterol 24-hydroxylase inhibitor, glycogen synthase kinase-3 beta inhibitors, and mTOR inhibitors have a promising antiepileptogenic effect. |
format | Online Article Text |
id | pubmed-10662271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-106622712023-10-01 Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets Belete, Tafere Mulaw Ann Neurosci Review Articles BACKGROUND: Epilepsy is a chronic neurological disorder that affects approximately 50–70 million people worldwide. Epilepsy has a significant economic and social burden on patients as well as on the country. The recurrent, spontaneous seizure activity caused by abnormal neuronal firing in the brain is a hallmark of epilepsy. The current antiepileptic drugs provide symptomatic relief by restoring the balance of excitatory and inhibitory neurotransmitters. Besides, about 30% of epileptic patients do not achieve seizure control. The prevalence of adverse drug reactions, including aggression, agitation, irritability, and associated comorbidities, is also prevalent. Therefore, researchers should focus on developing more effective, safe, and disease-modifying agents based on new molecular targets and signaling cascades. SUMMARY: This review overviews several clinical trials that help identify promising new targets like lactate dehydrogenase inhibitors, c-jun n-terminal kinases, high mobility group box-1 antibodies, astrocyte reactivity inhibitors, cholesterol 24-hydroxylase inhibitors, glycogen synthase kinase-3 beta inhibitors, and glycolytic inhibitors to develop a new antiepileptic drug. KEY MESSAGES: Approximately 30% of epileptic patients do not achieve seizure control. The current anti-seizure drugs are not disease modifying, cure or prevent epilepsy. Lactate dehydrogenase inhibitor, cholesterol 24-hydroxylase inhibitor, glycogen synthase kinase-3 beta inhibitors, and mTOR inhibitors have a promising antiepileptogenic effect. SAGE Publications 2023-08-17 2023-10 /pmc/articles/PMC10662271/ /pubmed/38020406 http://dx.doi.org/10.1177/09727531231185991 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Articles Belete, Tafere Mulaw Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets |
title | Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets |
title_full | Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets |
title_fullStr | Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets |
title_full_unstemmed | Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets |
title_short | Recent Progress in the Development of New Antiepileptic Drugs with Novel Targets |
title_sort | recent progress in the development of new antiepileptic drugs with novel targets |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662271/ https://www.ncbi.nlm.nih.gov/pubmed/38020406 http://dx.doi.org/10.1177/09727531231185991 |
work_keys_str_mv | AT beletetaferemulaw recentprogressinthedevelopmentofnewantiepilepticdrugswithnoveltargets |